Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | DRD3 | P35462 | 5/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7836915 | 0.75 | L3MBTL3 (0.31) | L3MBTL3L3MBTL1 | |
| SCHEMBL4636682 | 0.74 | SLC18A3 (0.54) | ALDH1A1GRIN2BSLC18A3DRD2DRD3 | |
| SCHEMBL2380226 | 0.73 | CHRNA7 (0.44) | ALDH1A1GRIN2BSLC18A3DRD2DRD3 | |
| SCHEMBL21447979 | 0.72 | L3MBTL3 (0.52) | ALDH1A1GRIN2BDRD2DRD3MBTD1 | |
| SCHEMBL9046550 | 0.72 | SLC2A1 (0.40) | ALDH1A1GRIN2BSLC18A3DRD2DRD3 | |
| SCHEMBL11555679 | 0.71 | GRIN2B (0.42) | ALDH1A1GRIN2BSLC18A3DRD2DRD3 | |
| Hydrochloric Acid SCHEMBL27659479 | 0.71 | L3MBTL3 (0.50) | ALDH1A1GRIN2BDRD2DRD3MBTD1 | |
| SCHEMBL11560634 | 0.69 | SLC18A3 (0.52) | ALDH1A1GRIN2BSLC18A3DRD2DRD3 | |
| SCHEMBL7006449 | 0.68 | PIM1 (0.32) | — | |
| SCHEMBL13174962 | 0.66 | MCHR1 (0.56) | DRD2MBTD1L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | ALDH1A1 2102/4885GRIN2B 3648/4885SLC18A3 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.